bluuebunny/crossref_metadata_2025 huggingface dataset:
Lemierre Syndrome with Extensive Thrombosis: A Unique Case Report and Literature Review
Authors: Koukias Stergos , Athousaki Asimenia , Klonaris Dionisios , Kavousanaki Melina , Papazoglou Georgios , Papanikolaou Nikolaos
Published: September 2024

Background. Lemierre syndrome (LS) is a rare complication of upper aerodigestive tract infections characterized by proximal and distal septic emboli, commonly including internal jugular vein (IJV) thrombosis. Diagnosis can be challenging, and treatment delays can result in increased patient morbidity and mortality. We present a rare case of LS with extensive thrombosis and multiple sites of distal infection and a narrative review of the literature. Case Presentation. A 52‐year‐old Caucasian male was transferred to the emergency department (ED) with an altered level of consciousness and clinical findings of acute bacterial pharyngotonsillitis. Medical history included cervical spine disorder and traumatic brain injury in the past, as well as the recent use of pain relievers due to acute cervical pain. Imaging studies revealed left IJV thrombosis that extended into multiple venous cerebral sinuses and infiltrates of the right lung. LS was considered the most likely diagnosis. The patient was intubated and transferred to the intensive care unit (ICU). Treatment included intravenous broad‐spectrum antibiotics and anticoagulation therapy. Response to treatment was satisfactory. After extubation, he was transferred to a ward and discharged with resolution of clinical and imaging findings. Conclusion. LS is a rare disease and may have an insidious course. Timely diagnosis and appropriate treatment strategies, mainly broad‐spectrum antibiotics, offer favorable outcomes in otherwise healthy individuals. The indications for anticoagulation therapy still remain controversial. Anticoagulants are usually administered to patients with extensive thrombosis. Surgical treatment includes abscess drainage, while IJV ligation and excision are reserved for nonresponders to medical treatment.
Supplementary Table S7 from Long-Term Risks of Cardiovascular Death among Older Patients with Major Hematological Malignancies: A Population-Based Cohort Study from SEER Database
Authors: Zhang Hanqing , He Minghao , Zhang Peng , Gao Yang , Ouyang Ling , He Xianjun , Han Na , Zhang Jinfeng , Guan Mengshan , Feng Yueqi , Li Yonghua
Published: September 2024

Supplementary Table S7. Absolute excess risks for Specific CVD death in older patients with hematological malignancies based on years after diagnosis.
Supplementary Table S5 from Long-Term Risks of Cardiovascular Death among Older Patients with Major Hematological Malignancies: A Population-Based Cohort Study from SEER Database
Authors: Zhang Hanqing , He Minghao , Zhang Peng , Gao Yang , Ouyang Ling , He Xianjun , Han Na , Zhang Jinfeng , Guan Mengshan , Feng Yueqi , Li Yonghua
Published: September 2024

Supplementary Table S5. Standardized Mortality Ratios for Specific CVD death in older patient with hematological malignancies based on characteristics.
Supplementary Figure S4 from Long-Term Risks of Cardiovascular Death among Older Patients with Major Hematological Malignancies: A Population-Based Cohort Study from SEER Database
Authors: Zhang Hanqing , He Minghao , Zhang Peng , Gao Yang , Ouyang Ling , He Xianjun , Han Na , Zhang Jinfeng , Guan Mengshan , Feng Yueqi , Li Yonghua
Published: September 2024

Supplementary Figure S4. The distribution of causes of deaths among older patients with hematological malignancies (1984-2003). For each panel, we show the distribution based on different causes of death, the distribution of all four causes of deaths (a), the distribution of all causes of non-malignancies deaths (b), the distribution of all causes of CVD-related deaths (c). The time interval does not include the upper limit. Abbreviations: CVD, Cardiovascular Disease
Supplementary Table S6 from Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer
Authors: Trendowski Matthew R. , Watza Donovan , Lusk Christine M. , Lonardo Fulvio , Ratliff Valerie , Wenzlaff Angela S. , Mamdani Hirva , Neslund-Dudas Christine , Boerner Julie L. , Schwartz Ann G. , Gibson Heather M.
Published: September 2024

Logistic Regression Results of TLS Status and Immune Gene Expression (ppooled < 0.05).
Supplementary Table S1 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Authors: van Berge Henegouwen Jade M. , Zeverijn Laurien J. , Geurts Birgit S. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , Huitema Alwin D.R. , de Vos Filip Y.F. , Grünberg Katrien , Bloemendal Haiko J. , Verheul Henk M.W. , Voest Emile E. , Gelderblom Hans
Published: September 2024

An overview of all granted waivers in DRUP
Supplementary Table S1 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Authors: Lentz Robert W. , Friedrich Tyler J. , Blatchford Patrick J. , Jordan Kimberly R. , Pitts Todd M. , Robinson Hannah R. , Davis S. Lindsey , Kim Sunnie S. , Leal Alexis D. , Lee Mathew R. , Waring Meredith R.N. , Martin Anne C. , Dominguez Adrian T.A. , Bagby Stacey M. , Hartman Sarah J. , Eckhardt S. Gail , Messersmith Wells A. , Lieu Christopher H.
Published: September 2024

Supplementary Table S1. Representativeness of Study Participants.
Supplementary Data S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: French Jena D. , Haugen Bryan R. , Worden Francis P. , Bowles Daniel W. , Gianoukakis Andrew G. , Konda Bhavana , Dadu Ramona , Sherman Eric J. , McCue Shaylene , Foster Nathan R. , Nikiforov Yuri E. , Farias Ticiana D.J. , Norman Paul J. , Wirth Lori J.
Published: September 2024

Clinical Trial Protocol
Supplementary Figure S1 from Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study
Authors: van der Vaart Thijs , Wijnenga Maarten M.J. , van Garderen Karin , Dubbink Hendrikus J. , French Pim J. , Smits Marion , Dirven Clemens M.F. , Kros Johan M. , Vincent Arnaud J.P.E. , van den Bent Martin J.
Published: September 2024

Supplementary Figure S1. Assessment of the linearity of the effect of age and tumor volume.
Supplementary Figure S10 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Classification of LUAD and SCLC cell lines based on H3K27ac ChIP-seq data.
Supplementary Table S6 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Table S6. Cell type counts for each patient.
Supplementary Table S5 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Table S5. Cell count, cell loss, and field of view count for each patient.
Supplementary Table S11 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Table S11. Differential expression of genes and cell types in EBV-positive and EBV-negative cHL.
Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Authors: Chen Monica F. , Yang Soo-Ryum , Tao Jessica J. , Desilets Antoine , Diamond Eli L. , Wilhelm Clare , Rosen Ezra , Gong Yixiao , Mullaney Kerry , Torrisi Jean , Young Robert J. , Somwar Romel , Yu Helena A. , Kris Mark G. , Riely Gregory J. , Arcila Maria E. , Ladanyi Marc , Donoghue Mark T.A. , Rosen Neal , Yaeger Rona , Drilon Alexander , Murciano-Goroff Yonina R. , Offin Michael
Published: September 2024

Supplemental Table 1. Baseline characteristics of patients with de novo and acquired BRAF fusions.
Supplemental Figure 6 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Authors: Chen Monica F. , Yang Soo-Ryum , Tao Jessica J. , Desilets Antoine , Diamond Eli L. , Wilhelm Clare , Rosen Ezra , Gong Yixiao , Mullaney Kerry , Torrisi Jean , Young Robert J. , Somwar Romel , Yu Helena A. , Kris Mark G. , Riely Gregory J. , Arcila Maria E. , Ladanyi Marc , Donoghue Mark T.A. , Rosen Neal , Yaeger Rona , Drilon Alexander , Murciano-Goroff Yonina R. , Offin Michael
Published: September 2024

Supplemental Figure 6. Oncoprint for acquired BRAF fusions.
Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Authors: Chen Monica F. , Yang Soo-Ryum , Tao Jessica J. , Desilets Antoine , Diamond Eli L. , Wilhelm Clare , Rosen Ezra , Gong Yixiao , Mullaney Kerry , Torrisi Jean , Young Robert J. , Somwar Romel , Yu Helena A. , Kris Mark G. , Riely Gregory J. , Arcila Maria E. , Ladanyi Marc , Donoghue Mark T.A. , Rosen Neal , Yaeger Rona , Drilon Alexander , Murciano-Goroff Yonina R. , Offin Michael
Published: September 2024

Supplemental Figure 3. Structures of top 13 most common BRAF fusion isoforms.
Supplementary Figure S2 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Authors: Choi Yoonha , Dharia Neekesh V. , Jun Tomi , Chang Julie , Royer-Joo Stephanie , Yau Kenneth K. , Assaf Zoe J. , Aimi Junko , Sivakumar Smruthy , Montesion Meagan , Sacher Adrian , LoRusso Patricia , Desai Jayesh , Schutzman Jennifer L. , Shi Zhen
Published: September 2024

Supplementary Figure S2
Supplementary Figure S1 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Authors: Choi Yoonha , Dharia Neekesh V. , Jun Tomi , Chang Julie , Royer-Joo Stephanie , Yau Kenneth K. , Assaf Zoe J. , Aimi Junko , Sivakumar Smruthy , Montesion Meagan , Sacher Adrian , LoRusso Patricia , Desai Jayesh , Schutzman Jennifer L. , Shi Zhen
Published: September 2024

Supplementary Figure S1
Supplementary Figure S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Figure S3. Gene expression comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT) by whole transcriptome analysis.
Supplementary Figure S13 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Figure S13. Dose titration of commonly used cytotoxic agents against LUAC (n = 6) and LUSC (n = 6) cell lines.
Data from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Authors: Rey-Búa Beatriz , Grande Carlos , Sánchez Blanco José J. , Abrisqueta Pau , Gutiérrez Antonio , Ramírez Páyer Ángel , Giné Eva , Zeberio Etxetxipia Izaskun , Terol Maria J. , de la Cruz Vicente Fátima , Andreu Rafel , Ramirez Maria J. , de la Fuente Adolfo , Viguria Maria C. , Peñarrubia María J. , Jiménez-Ubieto Ana , Montes-Moreno Santiago , López-Guillermo Armando , Caballero María D. , Martín García-Sancho Alejandro
Published: September 2024

AbstractPurpose:
This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
Patients and Methods:
The IBDCL trial (NCT02692248) included patients with histologic diagnosis of non-GCB DLBCL with relapsed or refractory disease and non-candidates for stem-cell transplantation. Patients received an induction treatment consisting of six or eight cycles of R-GemOx at standard doses every 2 weeks, in combination with ibrutinib (560 mg daily), followed by a maintenance treatment with ibrutinib for a maximum of 2 years. The primary objective was to evaluate the overall response rate after four cycles.
Results:
Sixty-four patients were included, 72% of them refractory to the last regimen. The overall response rate and complete remission rate after the fourth cycle were 53% [95% confidence interval (CI), 41–65] and 34% (95% CI, 24–46), respectively. Twenty-four (37%) patients started maintenance, and 7 (11%) completed the planned 2 years. After a median follow-up of 29.7 months (range: 0.4–48.6), the estimated 2-year progression-free survival and overall survival were 18% (95% CI, 8–28) and 26% (95% CI, 14–37), respectively. The most common grade ≥3 treatment-related adverse events were thrombocytopenia (44%), neutropenia (30%), and anemia (14%). Grade ≥3 infectious and cardiovascular treatment-related adverse events were reported in 6 (9%) and 1 (2%) patient, respectively.
Conclusions:
Ibrutinib in combination with R-GemOx, followed by ibrutinib maintenance, demonstrated encouraging antitumor activity with durable responses and a manageable toxicity in patients with non-GCB DLBCL.
Plasma Concentrations of Multiple Oxysterols and Risk of Colorectal Adenomas
Authors: Passarelli Michael N. , McDonald Jeffrey G. , Thompson Bonne M. , Pomares-Millan Hugo , Palys Thomas J. , Rees Judy R. , Barry Elizabeth L.
Published: September 2024

Oxysterols are metabolites of cholesterol that regulate the homeostasis of cholesterol, fatty acids, and glucose. These metabolites are generated throughout the body, either enzymatically or from oxidative stress, and are detectable in peripheral circulation. We previously reported that circulating 27-hydroxycholesterol (27-OHC), an endogenous selective estrogen receptor modulator, may be a risk factor for colorectal adenomas. Here, in addition to 27-OHC, we report on four other circulating oxysterols: 25-hydroxycholesterol, 24(S)-hydroxycholesterol, 7ɑ-hydroxycholesterol, and 4β-hydroxycholesterol. Oxysterol concentrations were measured using liquid chromatography/mass spectrometry from fasting plasma collected at baseline from 1,246 participants of the Vitamin D/Calcium Polyp Prevention Study, a multicenter adenoma chemoprevention trial. To evaluate multiple oxysterols simultaneously, we used both log-linear regression and Bayesian kernel machine regression models developed for analyses of complex mixtures adjusted for potential confounding factors. Higher circulating 7ɑ-hydroxycholesterol was associated with higher adenoma risk (Bayesian kernel machine regression–based multivariable-adjusted risk ratios (RR; for the 75th vs. 25th percentile, 1.22; 95% credible interval, CI, 1.04–1.42). In contrast, higher circulating 4β-hydroxycholesterol was associated with lower risk of these polyps (RR, 0.84; 95% CI, 0.71–0.99). The positive association with advanced adenoma risk that we previously reported for circulating 27-OHC persisted when controlling for other oxysterols (RR, 1.26; 95% CI, 0.98–1.62), including among those with advanced adenomas at baseline (RR, 1.75; 95% CI, 1.01–3.06).

Prevention Relevance: Circulating concentrations of multiple oxysterols measured at the time of an initial colorectal adenoma diagnosis may be risk factors for subsequent incidence of these lesions. Novel colorectal cancer prevention strategies may target oxysterol formation.
Figure S6 from Endoplasmic Reticulum Stress Potentiates the Immunosuppressive Microenvironment in Hepatocellular Carcinoma by Promoting the Release of SNHG6-Enriched Small Extracellular Vesicles
Authors: Liu Chengdong , Zhou Xiaohan , Zeng Hanyi , Yu Jiaping , Li Wenwen , Zhang Wanli , Liao Yanxia , Wang Haijian , Liu Li
Published: September 2024

Supplementary Fig. S6. SNHG6 serves as a predictor for immunotherapeutic efficacy.
Table S3 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Fluorochrome panel overview
Table S2 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Tissue overview
Figure S5 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Intratumoral cell populations identified from transcriptomic data.
Figure S3 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Progression free survival and overall survival related for NIVO and CTRL patients.
Figure S16 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Detection of NARTs in YTILs, REP TILs and ex vivo PBMCs
Figure S15 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Proteomics comparison of samples from patients with tumor reactive and non-reactive TILs in the Nivolumab treated patient group.
Supplementary Figure S1 from PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination
Authors: Franzolin Giulia , Brundu Serena , Cojocaru Carina F. , Curatolo Aurora , Ponzo Matteo , Mastrantonio Roberta , Mihara Emiko , Kumanogoh Atsushi , Suga Hiroaki , Takagi Junichi , Tamagnone Luca , Giraudo Enrico
Published: September 2024

PLXNB1 inhibition does not affect 4T1 cells extravasation to the lung and their ability to adhere to endothelial cells
Supplementary Figure S2 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Authors: Sulsenti Roberta , Scialpi Giuseppina B. , Frossi Barbara , Botti Laura , Ferri Renata , Tripodi Irene , Piva Annamaria , Sangaletti Sabina , Pernici Davide , Cancila Valeria , Romeo Francesco , Chiodoni Claudia , Lecis Daniele , Bianchi Francesca , Fischetti Irene , Enriquez Claudia , Crivelli Filippo , Bregni Marco , Renne Giuseppe , Pece Salvatore , Tripodo Claudio , Pucillo Carlo E. , Colombo Mario P. , Jachetti Elena
Published: September 2024

Supplementary Figure S2. OPN evaluation in bone marrow-derived MCs. A. Separate channels of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue) of WT and OPN-/- MCs showed in Fig. 1A B. Representative images of 3 different biological replicates of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue), in WT and OPN-/- MCs. These pictures were used for the quantification reported in Fig. 1B.
Figure S1 from MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming
Authors: Zewdie Eden Y. , Edwards George M. , Hunter Debra M. , Earp Henry Shelton , Holtzhausen Alisha
Published: September 2024

Supplemental Figure 1
Supplementary Figure 7 from Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis
Authors: Castro-Pando Susana , Howell Rian M. , Li Le , Mascaro Marilina , Faraoni Erika Y. , Le Roux Olivereen , Romanin David , Tahan Virginia , Riquelme Erick , Zhang Yu , Kolls Jay K. , Allison James P. , Lozano Guillermina , Moghaddam Seyed J. , McAllister Florencia
Published: September 2024

Supplementary Figure 7: Identification of IL-17-producing cell types
Supplementary Table 2 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy
Authors: Porte Sarah , Audemard-Verger Alexandra , Wu Christian , Durand Aurélie , Level Théo , Giraud Léa , Lombès Amélie , Germain Mathieu , Pierre Rémi , Saintpierre Benjamin , Lambert Mireille , Auffray Cédric , Peyssonnaux Carole , Goldwasser François , Vaulont Sophie , Alves-Guerra Marie-Clotilde , Dentin Renaud , Lucas Bruno , Martin Bruno
Published: September 2024

Epidemiological features of studied patients with lung cancer.
Supplementary Figure 3 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy
Authors: Porte Sarah , Audemard-Verger Alexandra , Wu Christian , Durand Aurélie , Level Théo , Giraud Léa , Lombès Amélie , Germain Mathieu , Pierre Rémi , Saintpierre Benjamin , Lambert Mireille , Auffray Cédric , Peyssonnaux Carole , Goldwasser François , Vaulont Sophie , Alves-Guerra Marie-Clotilde , Dentin Renaud , Lucas Bruno , Martin Bruno
Published: September 2024

Iron supplementation does not inhibit MC38 and LLC tumor-cell proliferation in vitro.
Supplemental Figure S6 from Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
Authors: De Munter Stijn , Buhl Juliane L. , De Cock Laurenz , Van Parys Alexander , Daneels Willem , Pascal Eva , Deseins Lucas , Ingels Joline , Goetgeluk Glenn , Jansen Hanne , Billiet Lore , Pille Melissa , Van Duyse Julie , Bonte Sarah , Vandamme Niels , Van Dorpe Jo , Offner Fritz , Leclercq Georges , Taghon Tom , Depla Erik , Tavernier Jan , Kerre Tessa , Drost Jarno , Vandekerckhove Bart
Published: September 2024

Single cell analysis of nanoCAR T-cell treated mice result in 12 defined clusters.
Movie 1 from Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
Authors: De Munter Stijn , Buhl Juliane L. , De Cock Laurenz , Van Parys Alexander , Daneels Willem , Pascal Eva , Deseins Lucas , Ingels Joline , Goetgeluk Glenn , Jansen Hanne , Billiet Lore , Pille Melissa , Van Duyse Julie , Bonte Sarah , Vandamme Niels , Van Dorpe Jo , Offner Fritz , Leclercq Georges , Taghon Tom , Depla Erik , Tavernier Jan , Kerre Tessa , Drost Jarno , Vandekerckhove Bart
Published: September 2024

CD70-specific nanoCAR T-cells incubated with CD70+ JD033T organoid line
Data from Endoplasmic Reticulum Stress Potentiates the Immunosuppressive Microenvironment in Hepatocellular Carcinoma by Promoting the Release of SNHG6-Enriched Small Extracellular Vesicles
Authors: Liu Chengdong , Zhou Xiaohan , Zeng Hanyi , Yu Jiaping , Li Wenwen , Zhang Wanli , Liao Yanxia , Wang Haijian , Liu Li
Published: September 2024

Abstract
Endoplasmic reticulum (ER) stress leads to hepatocellular carcinoma (HCC) progression. Small extracellular vesicles (sEV) play a crucial role in modulating the tumor microenvironment (TME) by influencing cellular communication and immune responses. However, it is unclear whether ER stress modulates the TME through sEVs. In the current study, we investigated the effects and underlying mechanisms of ER stress on the HCC TME. In vivo and in vitro experiments showed that overactivated ER stress was a salient attribute of the immunosuppressive HCC TME. This was caused by the ATF4-promoted release of small nucleolar RNA host gene 6 (SNHG6)-carrying sEVs, which attenuated T cell-mediated immune responses. Overall, SNHG6 modulated the immunosuppressive TME and aggravated ER stress. Meanwhile, targeting SNHG6 facilitated M1-like macrophage and CD8+ T-cell infiltration and decreased the proportion of M2-like macrophages. In addition, SNHG6 knockdown enhanced anti-PD1 immunotherapeutic efficacy. Moreover, in HCC patients, overexpression of SNHG6 was associated with a lack of response to anti-PD1 therapy and poor prognosis, whereas low SNHG6 expression was associated with improved therapeutic efficacy and prognoses. These data indicate that a correlation exists among ER stress, sEVs, immunosuppressive HCC TME, and immunotherapeutic efficacy. Hence, SNHG6-targeted therapy may represent an effective strategy for patients with HCC.
Supplementary Table 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Authors: Stella Federico , Chiappella Annalisa , Casadei Beatrice , Bramanti Stefania , Ljevar Silva , Chiusolo Patrizia , Di Rocco Alice , Tisi Maria C. , Carrabba Matteo G. , Cutini Ilaria , Martino Massimo , Dodero Anna , Bonifazi Francesca , Santoro Armando , Sorà Federica , Botto Barbara , Barbui Anna M. , Russo Domenico , Musso Maurizio , Grillo Giovanni , Krampera Mauro , Olivieri Jacopo , Ladetto Marco , Cavallo Federica , Massaia Massimo , Arcaini Luca , Pennisi Martina , Zinzani Pier L. , Miceli Rosalba , Corradini Paolo
Published: September 2024

Supplementary Table 2 – Bivariable Cox model CAR-HEMATOTOX in tisa-cel and axi-cel
Supplementary Figure 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Authors: Stella Federico , Chiappella Annalisa , Casadei Beatrice , Bramanti Stefania , Ljevar Silva , Chiusolo Patrizia , Di Rocco Alice , Tisi Maria C. , Carrabba Matteo G. , Cutini Ilaria , Martino Massimo , Dodero Anna , Bonifazi Francesca , Santoro Armando , Sorà Federica , Botto Barbara , Barbui Anna M. , Russo Domenico , Musso Maurizio , Grillo Giovanni , Krampera Mauro , Olivieri Jacopo , Ladetto Marco , Cavallo Federica , Massaia Massimo , Arcaini Luca , Pennisi Martina , Zinzani Pier L. , Miceli Rosalba , Corradini Paolo
Published: September 2024

Supplementary Figure 1 – Survival in entire population
Unprocessed Western blots from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Authors: Meriranta Leo , Sorri Selma , Huse Kanutte , Liu Xiaonan , Spasevska Ivana , Zafar Sadia , Chowdhury Iftekhar , Dufva Olli , Sahlberg Eerika , Tandarić Luka , Karjalainen-Lindsberg Marja-Liisa , Hyytiäinen Marko , Varjosalo Markku , Myklebust June H. , Leppä Sirpa
Published: September 2024

Unprocessed Western blots for Figures 1E, 3I, 4E, 4F, 5A, 5S5, 5E, 5F, 5G, 5H, 7D, 7K, S5G, S5H, and S9A
Table S5 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Authors: Meriranta Leo , Sorri Selma , Huse Kanutte , Liu Xiaonan , Spasevska Ivana , Zafar Sadia , Chowdhury Iftekhar , Dufva Olli , Sahlberg Eerika , Tandarić Luka , Karjalainen-Lindsberg Marja-Liisa , Hyytiäinen Marko , Varjosalo Markku , Myklebust June H. , Leppä Sirpa
Published: September 2024

Table S5 shows data from the co-localization analysis of KLHL6 and BANK1 and analysis of protein-protein interactions of KLHL6 variants identified with proximity-ligation with C-terminal BioID2 constructs.
Table S2 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Authors: Meriranta Leo , Sorri Selma , Huse Kanutte , Liu Xiaonan , Spasevska Ivana , Zafar Sadia , Chowdhury Iftekhar , Dufva Olli , Sahlberg Eerika , Tandarić Luka , Karjalainen-Lindsberg Marja-Liisa , Hyytiäinen Marko , Varjosalo Markku , Myklebust June H. , Leppä Sirpa
Published: September 2024

Table S2 shows recurrent KLHL6 mutations reported in DLBCL.
Figure 2 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Authors: Meriranta Leo , Sorri Selma , Huse Kanutte , Liu Xiaonan , Spasevska Ivana , Zafar Sadia , Chowdhury Iftekhar , Dufva Olli , Sahlberg Eerika , Tandarić Luka , Karjalainen-Lindsberg Marja-Liisa , Hyytiäinen Marko , Varjosalo Markku , Myklebust June H. , Leppä Sirpa
Published: September 2024

Recurrent KLHL6 mutations and their impact on subcellular localization in lymphoma cells. A, Lollipop plot of KLHL6 mutations reported in 303 DLBCL tumors. B, Bar plots showing the fraction of different amino acid (AA) changes according to the most recurrently mutated AA residues in DLBCLs. Most common AA replacement per residue highlighted as the left hand side bar. C, Evolutionary conservation of KLHL6 AA sequences in the vicinity of the most frequently mutated AA residues across selected species. D, Predicted three-dimensional (3D) structure of KLHL6 according to in silico modeling using AlphaFold. Protein domains are shown with different color shading, and recurrently mutated AA residues are highlighted. E, 3D model of KLHL6 Kelch domain seen from above with recurrently mutated glutamic acid residues E547 and E568 shown. Inlet highlights colocalization. F and G, Genetic (F) and protein localization (G) features differentially associated with KLHL6 mutations in exon one (encoding the BTB hotspot) and Kelch domain. F, Mutations enriched in other genes co-occurring with different types of KLHL6 mutations in the Lacy and colleagues data set (n = 928; ref. 38). Genes mutated in ≥5% of the patients included in the analysis. Boxed rows indicate enriched genomic drivers (Fisher exact < 0.05), genes with FDR < 0.1 bolded. G, Co-occurrence with KLHL6 staining patterns according to KLHL6GC+ status in the discovery cohort (n = 110). H, Light microscopy images of diagnostic DLBCL tissue sections immunohistochemically stained for KLHL6 from patients with different KLHL6 mutations according to the original variant calls or re-analysis. Annotated AA changes of mutations highlighted per representative figure. Red arrowheads indicate aberrant puncta in tissues with KLHL6L65P mutation. Black arrowheads indicate KLHL6GC+ pattern. Scale bars, 50 μm (10 μm for inlets). I, Representative IF microscopy images of GCB cell lines SuDHL5 and Ocily7 and ABC cell line U2932 with ectopic expression of KLHL6 WT or mutants indicated on the top. Black arrowheads indicate representative KLHL6GC+ patterns and red arrowheads indicate aberrant vesicles of KLHL6L65P. Scale bar, 10 μm. J, Representative IF microscopy images of SuDHL5 cells expressing KLHL6L65P, KLHL6L90F, or KLHL6E547K mutants. Cells co-stained for KLHL6 and Golgi marker GM130. Co-stainings of other mutants shown in Supplementary Fig. S2E. Scale bar, 10 μm.
Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Authors: Zhou Cindy Q. , Li Ariel , Ri Kaoru , Sultan Ahmed S. , Ren Hening
Published: September 2024

Anti-HDGF antibody enhances the efficacy of EGFR-targeted therapy. Mice with established PDXs of NSCLC tumors were randomized into two arms (n = 6 each) to receive osimertinib or osimertinib plus anti-HDGF antibody. A and B, Spider plot of tumor volume changes in mice treated with osimertinib or osimertinib plus anti-HDGF antibody. C and D, Waterfall plot of best percent change from baseline of each tumor in the two treatment arms. E and F, Mean percent change from baseline in the two treatment arms. Asterisks mark the data point in which there is a significant difference between the two treatment arms. G and H, Kaplan–Meier plot of PFS of mice in the two treatment arms. Graphs show the results of TM00219 (A, C, E, and G) and TM00199 (B, D, F, and H).
Multiple Cerebral Infarcts and Encephalopathy as the First Clinical Manifestations of Hypereosinophilic Syndrome: A Case Report and Narrative Review
Authors: Romano Sonia , Avola Giulia , Angeli Marco Cesare , Brazzale Francesca , Giacopazzi Elena , Castellini Paola , Genovese Antonio
Published: September 2024

Background: Hypereosinophilic syndrome is characterized by a peripheral blood eosinophil count >1.5 × 103/μL on two different examinations within a month of each other and/or a 20% or higher percentage of eosinophils in a bone marrow section, associated with organ damage. Rarely, neurological manifestations may occur, even in the early stages. We report a case of idiopathic hypereosinophilic syndrome with Loeffler endocarditis presenting with multiple bilateral strokes and encephalopathy as the first clinical manifestations. Summary: Hypereosinophilia and echocardiographic findings suggested a Loeffler’s endocarditis. Blood hyperviscosity and small vessels inflammation induced by the hypereosinophilia itself, the embolization of intracardiac thrombus, along with the impaired clearance of microthrombi in the watershed areas, are the main mechanisms involved in the pathophysiology of stroke in the hypereosinophilic syndrome. Additionally, encephalopathy could be considered as a consequence of multiple cerebral infarcts and neurotoxicity induced by hypereosinophilia since our patient’s confusion and aggressive behavior gradually remitted after steroid therapy was started. Key Messages: To the best of our knowledge, our case report is a rare instance highlighting neurological involvement as the earliest manifestation of hypereosinophilia. We aimed to elucidate the central nervous system involvement in this intriguing disorder, with the goal of encouraging clinicians to consider hypereosinophilic syndrome in the diagnostic assessment of rare stroke etiologies.
Effectiveness and Safety of Intramatricial Triamcinolone Acetonide for Trachyonychia: A Retrospective Data Analysis
Authors: Grover Chander , Aggarwal Bharti , Ray Subhojit
Published: September 2024

Introduction: Trachyonychia is a clinical presentation characterised by dry, rough, longitudinally ridged nails or opalescent shiny nail plates with pits. Intramatricial steroids are an accepted form of therapy, but efficacy data are lacking. Materials and Methods: A retrospective data analysis of 6 patients (84 nails) with trachyonychia who received treatment for at least 6 sessions, with intramatricial triamcinolone acetonide (TA) (5 mg/mL), administered at 4 weekly intervals, was conducted. Photographic records were analysed for scoring severity of disease with Nail Surface Abnormality Index (NSI) score. Endpoint of therapy was 4 weeks after the sixth injection. Results: Among the 6 patients analysed as per protocol, 4 had both finger and toenails involved, while 2 had only fingernails affected. Overall 56/60 fingernails (93.3%) and 28/60 toenails (46.6%) were affected in these patients, and were treated. The mean baseline NSI score for fingernails was 10.34 ± 4.1 (range 2–16) which improved to 6.61 ± 3.21 (range 0–12 at endpoint, showing a 37.86% reduction [p < 0.0001]). The mean baseline NSI score of toenails improved from 10.25 ± 3.51 (range 4–14) to 5.00 ± 1.91 (range 1–8) at endpoint, showing a 50.05% reduction (p < 0.0001). Adverse effects included pain (5.88%), subungual hematoma (5.88%), proximal nail fold hyperpigmentation (21.17%), and atrophy (22.35%). Conclusion: Intramatricial TA is a safe and effective modality for treating trachyonychia.
Obstruktive Schlafapnoe: Risikofaktor für einen schweren COVID-19-Verlauf
Authors: Galetke Wolfgang
Published: September 2024

Obstruktive Schlafapnoe und schlafbezogene Hypoxie werden in Zusammenhang mit einer erhöhten Hospitalisierungsrate und Sterblichkeit bei Patienten mit COVID-19 gebracht. In dieser Studie wurde der Zusammenhang zwischen obstruktiver Schlafapnoe (OSA), der Schwere von COVID-19 und der damit verbundenen Mortalität weiter untersucht. Zusätzlich wurde der Einfluss klinischer und demographischer Faktoren auf den Krankheitsverlauf von COVID-19 untersucht. In dieser retrospektiven Studie wurden erwachsene Patienten eingeschlossen, bei denen vor der Entdeckung der Omikron-Variante eine COVID-19-Infektion diagnostiziert wurde. Die Autoren verglichen die Schwere der COVID-19-Erkrankung und die Sterblichkeit in Abhängigkeit von der Diagnose einer OSA. Die Studienpopulation umfasste 44 275 Patienten, die positiv auf COVID-19 getestet wurden. Von diesen hatten 97% einen milden oder asymptomatischen Verlauf, 1,2% zeigten einen moderaten Verlauf und 1,8% einen schweren Verlauf. Eine OSA wurde bei 980 (2,2%) Patienten diagnostiziert. In einer multivariaten Analyse zeigte sich, dass die Diagnose einer OSA das Risiko für einen schweren Verlauf von COVID-19 um das 1,6-fache (95%-Konfidenzintervall: 1,1–2,4) im Vergleich zu milden Verläufen erhöhte. Es zeigte sich jedoch kein Anstieg der Sterblichkeit bei Patienten mit OSA. Interessanterweise hatten Patienten mit mittlerem und hohem sozioökonomischen Status ein 1,6-fach höheres Risiko für einen schweren COVID-19-Verlauf als Patienten aus der Gruppe mit niedrigem sozioökonomischen Status (95%-Konfidenzintervall (KI): 1,2–2,1 bzw. 95%-KI: 1,1–2,3). Das Sterberisiko aufgrund von COVID-19 war bei Patienten mit mittlerem und hohem sozioökonomischen Status 1,6- bzw. 3,1-mal höher (95%-KI: 1,1–2,5 bzw. 95%-KI: 1,8–5,3) als bei Patienten mit niedrigem sozioökonomischen Status. Die Diagnose einer OSA erwies sich als unabhängiger Risikofaktor für einen schweren COVID-19-Verlauf. Zudem stieg das Risiko für eine schwere COVID-19-Erkrankung und die damit verbundene Sterblichkeit mit höherem sozioökonomischem Status.
СТРУКТУРНІ ЗМІНИ ПЕЧІНКИ У ХВОРИХ РІЗНИХ ВІКОВИХ ГРУП ЗАЛЕЖНО ВІД ТРИВАЛОСТІ МЕХАНІЧНОЇ ЖОВТЯНИЦІ
Authors: КАНІКОВСЬКИЙ О. Є. , КАРИЙ Я. В. , ДОВГАНЬ І. П.
Published: September 2024

Мета роботи: вивчити структурні зміни печінки у хворих різних вікових груп залежно від тривалості механічної жовтяниці (МЖ).
Матеріали і методи. 50 хворих на МЖ були поділені на дві дослідні групи. І група (n=25) включала пацієнтів молодого (18–44 р.) і середнього віку (45–59 р.), ІІ групу (n=25) склали хворі похилого віку (60–74 р.) та старечого віку (75–90 р.). У кожній групі виділяли 5 підгруп хворих з різною тривалістю МЖ – до 7 діб, 7–14 діб, 14–21 доба, 21–28 діб, понад 28 діб.
Результати. У пацієнтів І групи при термінах МЖ до 7 діб, від 7 до 14 діб та у хворих ІІ групи з тривалістю МЖ до 7 діб морфологічні зміни печінки мали переважно зворотний перебіг і полягали у внутрішньопротоковому холестазі, запальній інфільтрації строми, дистрофії гепатоцитів. При термінах МЖ від 14 до 21 доби, від 21 до 28 доби у пацієнтів І групи і у хворих ІІ групи з тривалістю МЖ від 7 до 14 доби, від 14 до 21 доби зміни печінки мали як зворотний, так і незворотний перебіг у зв’язку з розвитком і прогресуванням внутрішньопротокового і внутрішньоклітинного холестазу, стромального гепатиту, вираженої дистрофії, дрібно- та великовогнищевого некрозу гепатоцитів, вираженого фіброзу. У пацієнтів І групи з тривалістю МЖ понад 28 діб та при тривалості МЖ від 21 до 28 доби та понад 28 діб у хворих ІІ групи морфологічні зміни печінки мали незворотний характер та полягали у множинних дифузних відкладаннях білірубіну поза- і внутрішньоклітинно, великовогнищевому некрозі гепатоцитів, вираженому фіброзі, розвитку цирозу печінки.
ОСОБЛИВОСТІ РОЗВИТКУ ОКСИДАТИВНОГО СТРЕСУ У ПЕЧІНЦІ ЩУРІВ РІЗНОЇ СТАТІ ІЗ МЕТАБОЛІЧНО АСОЦІЙОВАНОЮ СТЕАТОТИЧНОЮ ХВОРОБОЮ ПЕЧІНКИ І КОРЕКЦІЄЮ ЙОГО ІНОЗИТОЛОМ
Authors: СОПЕЛЬ О. В. , ДЕНЕФІЛЬ О. В.
Published: September 2024

Мета роботи: дослідити зміни продуктів порексидного оиснення ліпідів і активність антиоксидантів та морфологічні зміни у печінці щурів різної статі з метаболічно асоційованою стеатотичною хворобою печінки і корекцією їх інозитолом.
Матеріали і методи. Досліди виконано на 96 щурах різної статі. Тварин розділено на 4 групи – контроль, МАСХП 4 місяці, МАСХП 4 місяці + міо-інозитол, МАСХП 4 місяці + D-chiro-інозито. У групах МАСХП 4 тварини вживали замість води 20 % розчин фруктози протягом 4 місяців. Через 2 місяці від початку експерименту протягом 2 місяців щурам групи МАСХП 4 місяці + Міо- інозитол інтрагастрально вводили міо-інозитол (400 мг/кг), групи МАСХП 4 місяці + D-chiro-інозитол – D-chiro-інозитол (30 мг/кг). Проводили забір печінки для морфологічного дослідження, у її гомогенатах визначали вміст дієнових і трієнових кон’югатів (ДК, ТК), основ Шиффа (ОШ), ТБК-активних продуктів (ТБК-ап), супероксиддисмутазну і каталазну активності (СОД, КАТ).
Результати. У самців контрольної групи, порівняно з самицями, вищі ДК, ТК, ТБК-ап, менша СОД. У тварин з МАСХП різко зросли ДК, ТК, ОШ, ТБК-ап, СОД і КАТ, причому ДК, ТК залишалися більшими у самців, а ОШ – у самиць. Міо-інозитол спричинив менше накопичення ДК, ТК, ОШ, ТБК-ап, СОД і КАТ у самців і самиць, причому тільки КАТ була менша у самиць. D-chiro- інозитол теж привів до меншого накопичення ДК, ТК, ОШ, ТБКап, СОД і КАТ у самців і самиць, але у самиць були вищими ДК, у самців – ТБК-ап, КАТ. Порівняно з міо-інозитолом, D-chiro-інозитол у самиць показав більший ефект відносно СОД. Аналогічно, досліджувані препарати покращували морфологічний стан печінки, зменшуючи стеатогепатоз.
ІНТЕГРАЛЬНА ОЦІНКА СИСТЕМНИХ ПРОЯВІВ ТРАВМАТИЧНОЇ ХВОРОБИ ЗА УМОВ КРАНІОСКЕЛЕТНОЇ ТРАВМИ У ЩУРІВ РІЗНОЇ СТАТІ
Authors: ГУДИМА Ан. А. , ДЕНЕФІЛЬ О. В.
Published: September 2024

Мета роботи: зʼясувати вплив краніоскелетної травми на динаміку маркерів системних проявів травматичної хвороби у щурів різної статі.
Матеріали і методи. Експерименти проведено на білих щурах лінії Вістар масою 200–220 г різної статі. Щурів поділили контрольну (по 6 щурів самиць і самців та дослідну групи (по 45 щурів різної статі). В умовах тіопентало-натрієвого наркозу в дозі 40 мг∙кг-1 у дослідній групі моделювали КСТ. Контрольних щурів різної статі тільки вводили в наркоз. У щурів дослідної групи через 1, 3, 7, 14 та 28 діб посттравматичного періоду з метою оцінки ступеня активації центральних механізмів регуляції серцевого ритму проводили реєстрацію кардіоінтервалограми і розраховували індекс напруження регуляторних механізмів. Далі щурів умертвляли і в екстракті гомогенату серця визначали вміст реагентів до тіобарбітурової кислоти, в сироватці крові – вміст церулоплазміну.
Результати. За умов експериментальної краніоскелетної травми у самців, порівняно з самицями, в серці суттєво посилювалася інтенсивність процесів ліпідної пероксидації, свідченням чого був більший ступінь зростання вмісту в серці реагентів до тіобарбітурової кислоти через 7, 14 та 28 діб посттравматичного періоду. У самців експериментальна травма супроводжувалася тривалою прозапальною реакцією зі статистично вірогідно більшим зростанням, порівняно із самицями, вмісту в сироватці крові церулоплазміну, починаючи з 3 доби посттравматичного періоду. За умов модельованої травми відмічали посилення централізації управління серцевим ритмом, на що вказувало підвищення індексу напруження регуляторних систем, величина якого у щурів різної статі коливалася у протифазах: у самців зростала через 1 та 14 діб експерименту, у самиць – через 3 доби з наступним зниженням. Показник через 14 та 28 діб експерименту у самиць був статистично вірогідно меншим, ніж у самців.
Aplicando a teoria de Ian Mcharg: uma análise das perspectivas de planejamento territorial na sub-bacia do Córrego do Cafundó, em Sabará, Minas Gerais
Authors: Ferreira Rogério Ribeiro , Costa Aline Cristina Gonçalves da , Lopes Giovanna de Paula , Paranhos Elisabete Cunha de Andrade , Teixeira Maria Cristina Villefort
Published: September 2024

Localizada no município de Sabará, em Minas Gerais, a sub-bacia do Córrego do Cafundó é um dos únicos remanescentes não urbanizados da bacia do Ribeirão Arrudas, afluente do Rio das Velhas e cuja ocupação historicamente ocorreu considerando parcamente os recursos naturais ali presentes, com a retificação, a canalização e o tamponamento dos cursos hídricos, a excessiva impermeabilização do solo e o consequente agravamento dos problemas de drenagem. Tendo em vista o atual contexto de expansão e adensamento urbano da Região Metropolitana de Belo Horizonte, onde a bacia se insere, torna-se necessária a reflexão acerca de regiões, como a do Córrego do Cafundó, que podem sofrer processos de urbanização no futuro. Dessa forma, com base no método de Ian McHarg, apresentado em seu livro Design with Nature (1969), este trabalho busca investigar a aptidão dessa sub-bacia ao uso e ocupação do solo, particularmente sob a ótica da drenagem pluvial; avaliar a adequabilidade das legislações urbanísticas ali incidentes, em comparação com os dados obtidos; e, assim, repensar a pertinência da teoria de McHarg na contemporaneidade, diante das novas geotecnologias e do avanço das perspectivas sobre o planejamento sustentável.